• EE100 Costs of Home Mechanical Ventilation and Oxygen Therapy in Russia: Real-World Data

    Dec 1, 2023, 00:00

  • Health Policy Regulatory

    Dec 1, 2023, 00:00

  • CO64 Challenges Associated with Surrogate Endpoints for Healthcare Decision Making in Oncology

    Dec 1, 2023, 00:00

  • HTA58 Scoping Mock-Up: What Can We Learn From an EU-4 Experiment for EU HTA?

    Dec 1, 2023, 00:00

  • MSR159 A Novel Unanchored Simulated Treatment Comparison Approach for Time-to-Event Data

    Dec 1, 2023, 00:00

  • HSD82 Impact of the COVID-19 Pandemic in the Netherlands on Primary Healthcare Use and Clinical Outcomes in People with Type 2 Diabetes

    Dec 1, 2023, 00:00

  • EE326 Cost-Effectiveness of Multiparametric MRI (mpMRI) Compared to No Test for Monitoring of NASH Treatment in the UK

    Dec 1, 2023, 00:00

  • RWD49 Real-World Evidence From a Federated Data Network to Reduce Uncertainty in the Long-Term Extrapolations of Oncology Treatments

    Dec 1, 2023, 00:00

  • EE51 Rethinking Economic Evaluation in Amyotrophic Lateral Sclerosis Treatment: Embracing Alternative Model Conceptualizations

    Dec 1, 2023, 00:00

  • CO15 Clinical Outcomes of Patients with Relapsed/Refractory Large B-Cell Lymphoma Receiving Second-Line Therapy in England: A Multicenter, Retrospective, Real-World Study

    Dec 1, 2023, 00:00

  • EPH26 Assessing Cancer Related Premature Mortality and Productivity Loss in Lung, Melanoma, and Breast Cancers in European Regions: Temporal Trends in 2010-2019

    Dec 1, 2023, 00:00

  • HTA221 Improving the Reimbursement Application Process: A Predictive Model for Identifying Key Subgroup Specification Parameters for Anti-Obesity Medication

    Dec 1, 2023, 00:00

  • EPH182 Factors Associated with Augmentation Agent Use in Patients with Treatment-Resistant Depression

    Dec 1, 2023, 00:00

  • HTA329 The Race to Improve Health Technology Assessment of Gene Therapies: Which Countries Are Embracing Recommendations?

    Dec 1, 2023, 00:00

  • CO165 Validation of High Risk Criteria in Medication Reconciliation in Major Orthopedic Surgery: A Delphi Study

    Dec 1, 2023, 00:00

  • PT30 Will Health Technology Assessment (HTA) Bodies in Europe Accept Evidence from an External Control Arm to Supplement Evidence from Clinical Trials for Chronic Diseases?

    Dec 1, 2023, 00:00

  • EE738 Cost-Effectiveness of Renal Denervation for Uncontrolled Hypertension: An Analysis for Sweden Based on the SPYRAL HTN-ON MED Trial and Other Contemporary Evidence

    Dec 1, 2023, 00:00

  • EE659 Estimating the Economic Consequences of Migraine in Sweden: A Fiscal Model Using the Government Perspective of Costs

    Dec 1, 2023, 00:00

  • EE758 Modelling Visual Acuity Distributions to Inform a Simplified Cost Effectiveness Analysis

    Dec 1, 2023, 00:00

  • Using Discrete Choice Experiments to Elicit Carers' and Patients' Preferences

    Dec 1, 2023, 00:00

  • PCR195 Patient Voice in Smc Technology Appraisals for Orphan and Ultra-Orphan Diseases

    Dec 1, 2023, 00:00

  • PCR250 Management of Osteogenesis Imperfecta: Self-Reported Funding Sources for Healthcare, Consumables and Services Across the EU5 and Nordics

    Dec 1, 2023, 00:00

  • EE431 Evaluating the Budget Impact of NOVOCART Inject Plus (Ninject) for Symptomatic Knee Cartilage Defects in the NHS

    Dec 1, 2023, 00:00

  • P47 How Do HTA Agencies Manage Uncertainties in the Long-Term Clinical Benefit of Gene Therapies? An Analysis of Recent Gene Therapy HTAs in England, Germany, France, Italy, Canada, and the United States

    Dec 1, 2023, 00:00

  • EE494 Optimizing Treatment of Schizophrenia: Pharmacoeconomic Consequences and Potential for Patient Switching to Long-Acting Injectables

    Dec 1, 2023, 00:00

  • EE622 Improved Glycemic Outcomes and Associated Cost Savings with an Advanced Hybrid Closed Loop System for People with Type 1 Diabetes with Suboptimal Glycemic Control in Europe

    Dec 1, 2023, 00:00

  • CO133 Systematic Literature Review (SLR) of Clinical Data from First-Line Treatment or First-Line Maintenance Therapy for Advanced or Metastatic Ovarian Cancer (2010–2023)

    Dec 1, 2023, 00:00

  • SA16 Assessing the Validity of Observational Filters for Systematic and Rapid Literature Reviews

    Dec 1, 2023, 00:00

  • EE536 Cost-Effectiveness of Axicabtagene Ciloleucel (axi-cel) Vs Standard of Care for Adult Patients with Relapsed or Refractory Follicular Lymphoma as 4TH or Later Line Treatment in Sweden

    Dec 1, 2023, 00:00

  • Health Technology Assessment

    Dec 1, 2023, 00:00

  • EE511 Systematic Review of Cost Effectiveness Assessment Reports of Immune Checkpoint Inhibitors in Early and Advanced/Metastatic Stages of Cancer in France

    Dec 1, 2023, 00:00

  • EE172 An Early Economic Analysis of the Costs and Benefits of Medical Alert Assistance Dogs (MAADS) in the Management of Emergency Episodes for People with Postural Tachycardia Syndrome (POTS) Using Real-World Evidence (RWE)

    Dec 1, 2023, 00:00

  • EE436 Economic Evaluation of Transcatheter Versus Surgical Aortic Valve Replacement in Low- and Intermediate-Risk Patients with Severe Aortic Stenosis in China

    Dec 1, 2023, 00:00

  • EE677 Cost-Consequence of Using NGS vs Single-Testing in NSCLC Patients at Diagnosis – Real-World Data From a Portuguese Hospital

    Dec 1, 2023, 00:00

  • EE703 Economic Burden and Changing Treatment Landscape in Stargardt Disease: A Literature and Database Review

    Dec 1, 2023, 00:00

  • EE403 Economic Analysis of Dupilumab Use in Patients With Chronic Rhinosinusitis With Nasal Polyps in Colombia

    Dec 1, 2023, 00:00

  • HTA307 Evolving Principles for Defining and Assessing the Economic and Societal Value of Cancer Therapies

    Dec 1, 2023, 00:00

  • MSR142 Multi-State Modelling Incorporating a Combined Additive and Relative Hazards Model

    Dec 1, 2023, 00:00

  • EE452 Comparison of Disease Agnostic Healthcare Resource Utilization and Costs Across the US and EU5 Population

    Dec 1, 2023, 00:00

  • EE266 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Iron Deficiency Anemia in China

    Dec 1, 2023, 00:00

  • MSR133 What Factors Influence the Prescription of Oral Antivirals for COVID-19 in Japan? – a State Transitional Agent-Based Model Analysis

    Dec 1, 2023, 00:00

  • MSR77 Can Bayesian Informative Priors Improve Extrapolation of Immature Overall Survival? A Case Study in Advanced Melanoma

    Dec 1, 2023, 00:00

  • PCR180 The Life with Myasthenia Gravis: Socioeconomic Impact of the Disease on Patients in the Czech Republic

    Dec 1, 2023, 00:00

  • PCR38 A Systematic Literature Review of the Humanistic Burden Associated with Geographic Atrophy

    Dec 1, 2023, 00:00

  • PCR160 An Integrated Software Platform to Capture Patient Preference Data Throughout the Medical Product Lifecycle

    Dec 1, 2023, 00:00

  • HTA191 Discussion of Health Inequalities in the NICE Single Technology Appraisal Process: A Review of Recent Submissions in NHS England Core20PLUS5 Focus Clinical Areas

    Dec 1, 2023, 00:00

  • EPH32 Canadian Pustular Psoriasis Study (CAPPS): Examining Disease Burden, Treatments, and Healthcare Resource Utilization for Generalized Pustular Psoriasis Flares

    Dec 1, 2023, 00:00

  • EE287 Epidemiologic and Economic Impact of COVID-19 Vaccination Among at-Risk Individuals and Individuals Aged ≥60 Years in Germany

    Dec 1, 2023, 00:00

  • EPH219 The Effect of Gestational Weight Gain on Pregnancy Outcome

    Dec 1, 2023, 00:00

  • EE689 A Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment (Monotherapy) for Adult Patients With Non-Small Cell Lung Cancer Following Resection and Platinum-Based Chemotherapy in Greece

    Dec 1, 2023, 00:00

  • EE353 Incorporation of Cladribine for Patients With Multiple Sclerosis in a Health Insurance Company in Brazil: Cost-Effectiveness

    Dec 1, 2023, 00:00

  • HSD85 Patterns and Correlates of Physical Activity Among Nigerian Community-Dwelling Older Adults

    Dec 1, 2023, 00:00

  • CO194 Integration of Clinical Outcome Assessments (COA) in Drug Approval Process to Foster Patient-Centric Clinical Trials: A Review of 3 Regulatory Guidelines for Drug Development in the APAC

    Dec 1, 2023, 00:00

  • SA54 Quality of Life, Economic Burden, and Comorbidities Associated with Essential Tremor: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • CO191 Effectiveness of New Generation Heat and Moisture Exchangers and Adhesives for Laryngectomized Patients in Portugal

    Dec 1, 2023, 00:00

  • EPH121 Contraindicated Remdesivir Use Among Individuals Hospitalized Due to COVID-19: According to the Danish Treatment Guidelines

    Dec 1, 2023, 00:00

  • EE550 Lifetime Cost of Orphan Therapies in Paediatric Indications in Europe

    Dec 1, 2023, 00:00

  • EE409 The Costs of Unaddressed Hearing Loss as a Basis for Cost-Effectiveness Analyses

    Dec 1, 2023, 00:00

  • PCR174 The Patient-Centered Core Impact Set Taxonomy: A Practical Example of Use and Refinement Using Voice-of-the-Patient Reports and Patient Interviews

    Dec 1, 2023, 00:00

  • PCR49 A Preliminary Comparison between Analytical Hierarchy Process and Discrete Choice Experiment in Health State Preferences in Hong Kong SAR, China

    Dec 1, 2023, 00:00

  • P28 Medication Non-Adherence in Patients with Varying Levels of Depression Symptoms Measured Using the Medication Adherence Reasons Scale

    Dec 1, 2023, 00:00

  • RWD155 Using Real-World-Evidence to Inform Pathway Evaluations at NICE: Benefits and Challenges

    Dec 1, 2023, 00:00

  • MSR112 Assessing the Feasibility of Applying Natural Language Processing for Systematic Literature Reviews: A Case Study in Non-Small-Cell Lung Cancer

    Dec 1, 2023, 00:00

  • PCR87 Collecting Exploratory Patient Preference Data Using an Efficient Approach: An Example in Rare Diseases

    Dec 1, 2023, 00:00

  • Disclaimer

    Dec 1, 2023, 00:00

  • RWD112 Factors Associated with High Costs of Patients with Non-Alcoholic Fatty Liver Disease: An Observational Study Using the French Constances Cohort

    Dec 1, 2023, 00:00

  • MSR31 A Simulation Study to Examine the Influence of Varied Standard Deviation of Covariates across Trials on Population Adjusted Indirect Treatment Comparisons

    Dec 1, 2023, 00:00

  • SA4 Characterization of Demography and Comorbidity in Newly Diagnosed Multiple Myeloma Patients in the UK

    Dec 1, 2023, 00:00

  • HPR181 Comprehensive and Standardized Value Assessment of Innovative Cancer Treatments: A Multi-Criteria Decision Analysis (MCDA) Tool for Switzerland

    Dec 1, 2023, 00:00

  • EE58 Endometrial Cancer Care in Colombia: A Cost-of-Illness Study Based on Administrative Claims Databases

    Dec 1, 2023, 00:00

  • HTA175 The Impact of Accelerated Regulatory Approval on Health Technology Assessment: An Evaluation of Orphan Drugs in Four Markets

    Dec 1, 2023, 00:00

  • HTA330 EU HTA: How Will Joint Clinical Assessment (JCA) Address the Specifics of Gene Therapies?

    Dec 1, 2023, 00:00

  • HTA129 Learnings from TC Opinions of Drugs Evaluated for EAP Under New Process

    Dec 1, 2023, 00:00

  • EE306 Utilizing Real World Evidence for Cost-Effectiveness Analysis of the Disease Management Program for Chronic Heart Failure Herzmobil Tirol

    Dec 1, 2023, 00:00

  • HTA72 How Is Real-World Evidence (RWE) Being Used in Health Technology Assessment (HTA) Decisions? Qualitative Insights from Comparisons of Three RWE Study Types Across Multiple Jurisdictions

    Dec 1, 2023, 00:00

  • HTA102 Exploring Potential Inequity in Access to Medicines for Ultra-Rare Disease in England and Scotland: SMC Ultra-Orphan Pathway Versus NICE HST

    Dec 1, 2023, 00:00

  • EE153 Using a Cumulative Low-Density Lipoprotein Cholesterol Modelling Approach to Estimate the Reduction of Risk of Atherosclerotic Cardiovascular Events from a Primary Prevention Program

    Dec 1, 2023, 00:00

  • HPR94 Treating Early Often Comes Too Late: Ensuring Patient Access to Early Cancer Detection and Treatment in Europe

    Dec 1, 2023, 00:00

  • EE300 Looking Sharp! Applying Cutting-Edge Shapley Additive Explanation (SHAP) Approaches to Cost-Effectiveness Modelling in Contrast to One-Way Sensitivity Analysis

    Dec 1, 2023, 00:00

  • EE406 Budget Impact Analysis of Dupilumab 200 Mg for Treatment of Adolescent and Adult With Severe Asthma in Algerian Setting

    Dec 1, 2023, 00:00

  • EE479 The Cost of Treating Gastroesophageal Reflux Disease: A Systematic Review

    Dec 1, 2023, 00:00

  • EE362 A Budget Impact Analysis of Pertuzumab, Trastuzumab, and Chemotherapy in the Neoadjuvant Setting for HER2-Positive High-Risk Early Breast Cancer Patients: Insights from the Tuscany Regional Health Care System Perspective

    Dec 1, 2023, 00:00

  • PCR24 Patient and Caregiver Perceptions of Systemic Anticancer Treatments in Advanced Bladder Cancer (aBC): Results of a Social Media Listening (SML) Study Conducted in 5 European Countries (Eu5)

    Dec 1, 2023, 00:00

  • HSD121 Study of Effective Treatment of Genital Herpes in Women in Ukraine

    Dec 1, 2023, 00:00

  • OP6 Overcrowding and Boarding Time: Emergency Department Performance and Impacting Factors

    Dec 1, 2023, 00:00

  • MT66 Characteristics of Patients with Symptomatic Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Implantation (TAVI): A Real-World Study in Singapore

    Dec 1, 2023, 00:00

  • Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach

    Dec 1, 2023, 00:00

  • PT21 Evaluation and Reimbursement of Digital Therapeutics in Germany, France, Belgium and England

    Dec 1, 2023, 00:00

  • EPH183 The Effects of COVID-19 on Mental Health

    Dec 1, 2023, 00:00

  • MT11 Potential Budget Impact of Negative Pressure Wound Therapy with Instillation and Dwell Time Versus Control Therapies for Wound Management in Mexico

    Dec 1, 2023, 00:00

  • SA73 A Retrospective Cohort Study to Evaluate the Disease Burden, Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Breast Cancer in Dubai, United Arab Emirates

    Dec 1, 2023, 00:00

  • EE735 Cost of Chimeric Antigen Receptor (CAR) T-Cell Therapy Related Toxicities

    Dec 1, 2023, 00:00

  • SA62 A Methodological Approach for the Design of a Unique Post Market Clinical Follow-up Study for Standard and Custom-Made Devices According to EU Medical Device Regulation 2017/745

    Dec 1, 2023, 00:00

  • PT11 Overall Survival of Patients with Lung Cancer Newly Diagnosed in the Period of the COVID-19 Pandemic Compared to Patients with an Incident Diagnosis Before the Pandemic: A Retrospective Analysis of German Claims Data

    Dec 1, 2023, 00:00

  • MSR5 Accuracy of Automated Data Extraction for Systematic Literature Reviews

    Dec 1, 2023, 00:00

  • PCR124 Qualitative Exploration of the Patient Experience of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Via Concept Elicitation Interviews with Patients and Neurologists

    Dec 1, 2023, 00:00

  • PCR184 A Systematic Literature Review of Patient-Reported Outcomes With Nivolumab Across Lung Cancers

    Dec 1, 2023, 00:00

  • P8 The Dutch Lock Procedure for Reimbursement Works as Intended

    Dec 1, 2023, 00:00

  • EPH23 Diagnosis Patterns in Breast Cancer Women in Brazil: Inequities Among Public and Private Settings in São Paulo State

    Dec 1, 2023, 00:00

  • PCR4 Impact of Obesity on Health-Related Quality of Life, Sleep, and Work – a Multinational Survey

    Dec 1, 2023, 00:00

  • PCR47 Consumer Preferences for Attributes of Influenza Vaccines in the United States: Results from a Discrete-Choice Experiment Study

    Dec 1, 2023, 00:00

  • HTA204 A Retrospective of the HAS Economic Appraisals Over the Last Ten Years

    Dec 1, 2023, 00:00

  • MSR116 Unsupervised Clustering and Binary Classification Analysis for Predicting Long COVID Among Adults in EU4 and UK

    Dec 1, 2023, 00:00

  • PCR28 Facilitating and Accelerating Patient-Centered Outcomes Measures Awareness and Use in Clinical Research in Rare Diseases

    Dec 1, 2023, 00:00

  • P11 Real-World Evidence of Total Colonoscopy for Colorectal Cancer Screening Based on Test Performance RCTs

    Dec 1, 2023, 00:00

  • HTA349 Impact of Technical Exchanges on CEESP Reservations: Analysis of the 2022 CEESP Opinions

    Dec 1, 2023, 00:00

  • HPR146 Fit for Purpose Policy Recommendations Related to Funding, Pricing, and Procurement of Point-of-Care Tests Used in Patients With Respiratory Tract Infections

    Dec 1, 2023, 00:00

  • EE41 Cost Effectiveness of Romosozumab Followed by Alendronate Versus Teriparatide in the Treatment of Severe Osteoporosis in Greece

    Dec 1, 2023, 00:00

  • PT44 Cost-Effectiveness of Olaparib Vs. Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer – the Canadian Perspective

    Dec 1, 2023, 00:00

  • EE205 The Impact of the COVID-19 Pandemic on Physician Visits Among Patients Diagnosed with Breast Cancer and Heart Failure in the United States

    Dec 1, 2023, 00:00

  • EPH214 Estimating the Burden of Vaccine-Preventable Insect-Borne Diseases Without Vaccination Alternatives in Europe: What's Going on in Spain and Germany?

    Dec 1, 2023, 00:00

  • EE329 Budget Impact Analysis of Adding Risankizumab and Upadacitinib for the Treatment of Inflammatory Bowel Disease in the Kingdom of Saudi Arabia

    Dec 1, 2023, 00:00

  • HTA215 Utilization of RWE in HTA Appraisals in England, Scotland, Germany, and France

    Dec 1, 2023, 00:00

  • EE458 Benefits, Costs and Cost Effectiveness of a Chronic Heart Failure Disease Management Program for Austria – a Decision-Analytic Modeling Study

    Dec 1, 2023, 00:00

  • HTA242 Incorporating Health Inequalities (HIs) Considerations into United Kingdom (UK) HTA Decision Making and the Impact on Rare Disease Medicines

    Dec 1, 2023, 00:00

  • EE75 Cost Analysis of Managing Brain Metastases in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in Greece

    Dec 1, 2023, 00:00

  • EE534 Economic Burden of Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphoid Leukemia

    Dec 1, 2023, 00:00

  • PT29 Predicting PICOs for EU Joint Clinical Assessment: Lessons from PICOs in Relative Effectiveness Assessments (REA) from EUnetHTA Joint Action 3 Project

    Dec 1, 2023, 00:00

  • EPH130 Drug Utilization Patterns of Guanfacine Hydrochloride Indicated for Attention Deficit Hyperactivity Disorder in European Countries

    Dec 1, 2023, 00:00

  • MT75 Analysis of Manufacturer and Negotiated Price Differential of Digital Health Applications (DIGA) in Germany

    Dec 1, 2023, 00:00

  • EE461 An Italian Real-World Analysis of Economic Impact in Patients with Hypercholesterolemia Treated with Rosuvastatin/Ezetimibe as Free Vs Single-Pill Combination

    Dec 1, 2023, 00:00

  • EE586 Comparison of Enteral Nutritional Therapy to Induce and Maintain Remission in Paediatric Patients with Mild-to-Moderate Crohn’S Disease: A Cost-Effectiveness Analysis in the UK

    Dec 1, 2023, 00:00

  • EE430 Use of Single-Arm Trials in Health Technology Assessment Reviews of Axicabtagene Ciloleucel

    Dec 1, 2023, 00:00

  • CO52 Comparative Analysis of Tabelecleucel Versus Standard of Care in Patients with EBV+ PTLD Following Hematopoietic Cell Transplant (HCT) or Solid Organ Transplant (SOT)

    Dec 1, 2023, 00:00

  • HTA317 Comparing Ultra-Rare Disease Pathways Within the United Kingdom: Can Different Processes Lead to Market Access Variations?

    Dec 1, 2023, 00:00

  • EE745 Cost- Effectiveness of Pneumococcal Vaccination for Adults Aged 60 Years and Older in Peru

    Dec 1, 2023, 00:00

  • EE333 Cost-Effectiveness of Once-Weekly Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the UK

    Dec 1, 2023, 00:00

  • EE485 Cost-Effectiveness of a 4 Days-a-Week Triple Therapy in Persons Living with HIV: An Ancillary Study of the Anrs 170 Quatuor Noninferiority Trial

    Dec 1, 2023, 00:00

  • HPR32 Is NRDL Supporting Access or Hindering Access in China? A Time-Trend Analysis From 2017-2022

    Dec 1, 2023, 00:00

  • EPH257 Healthcare Resource Consumptions of Patients with Atopic Dermatitis through Italian Administrative Healthcare Data

    Dec 1, 2023, 00:00

  • EE695 Cost-Effectiveness of a New Multi-Lumen Infusion Device to Reduce Central Venous Line-Related Infections in a Neonatal Intensive Care Unit

    Dec 1, 2023, 00:00

  • HTA182 The EU Regulation on HTA: Developing an Adapted Market Access Framework for Pharmaceutical Assets

    Dec 1, 2023, 00:00

  • HPR177 Overview of Reimbursement Criteria for Bariatric Surgery in 23 Countries

    Dec 1, 2023, 00:00

  • HPR109 What Drives Socially Acceptable Costs in Outcomes Based Agreements? a Survey Studying Gene Therapies

    Dec 1, 2023, 00:00

  • HTA32 When Should the Conduct of RWE Studies Be Prioritized for Reimbursement: Insights from Canadian and Global Stakeholders

    Dec 1, 2023, 00:00

  • EE305 Cost-Effectiveness Analysis of Genetic Screening in First-Degree Relative of Hypertrophic Cardiomyopathy Patients From the Perspective of the Brazilian United Health System

    Dec 1, 2023, 00:00

  • HPR186 Implementation of Risk-Sharing Agreement in Patients with Lung Cancer Treated with Immunotherapy Based on RWD in the Czech Republic

    Dec 1, 2023, 00:00

  • EE109 Healthcare Resource Utilization Among Patients with Transfusion-Dependent Beta-Thalassemia in France

    Dec 1, 2023, 00:00

  • EE65 Evaluating the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Strategy in Oncology and Implications for Policy: A Literature Review

    Dec 1, 2023, 00:00

  • MSR110 Four Alternative Methodologies for Simulated Treatment Comparison: How Could the Use of Simulation be Re-Invigorated

    Dec 1, 2023, 00:00

  • MSR163 Artificial Intelligence (AI)-Based Screening: Exploration of Differences in Two Health Technology Assessment (HTA)-Compliant Systematic Literature Reviews (SLRS)

    Dec 1, 2023, 00:00

  • EE713 Cost-of-Illness of Generalized Pustular Psoriasis in Italy

    Dec 1, 2023, 00:00

  • HTA277 Requirements for Clinical Evidence for Health Technology Assessment Submissions Across Different Countries

    Dec 1, 2023, 00:00

  • EPH146 Epidemiological Insights in Cutaneous Lupus Erythematosus: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE386 Budget Impact of Durvalumab for the Treatment of Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Brazilian Private Healthcare System

    Dec 1, 2023, 00:00

  • EPH131 Landscape Analysis of Alzheimer's Disease-Specific Caregiver Outcome Assessments

    Dec 1, 2023, 00:00

  • MSR50 Comparing Treatment Options for Fabry Disease: Feasibility Assessment for Network Meta-Analysis (NMA)

    Dec 1, 2023, 00:00

  • EE67 Insurer and Patient Costs for Repeat Breast Surgery After Initial Lumpectomy for Breast Cancer

    Dec 1, 2023, 00:00

  • EE61 Relationship between Health-Related Quality of Life and Productivity Loss and Indirect Costs of Leukemia and Lymphoma Patients and Caregivers: Estimates from a Cross-Sectional Study from Portugal

    Dec 1, 2023, 00:00

  • HPR40 DiGA in Germany: Achievable Prices After Price Negotiation or a Decision of the Arbitration Board

    Dec 1, 2023, 00:00

  • PCR56 Is Walking As Important As Muscle Strength After Stroke? Preference Weighting of ICF's Core Elements

    Dec 1, 2023, 00:00

  • PCR241 The Experience of Patients Living with Multiple Myeloma: Unmet Needs Associated with Diagnosis, Treatment, and Living with the Condition

    Dec 1, 2023, 00:00

  • HSD59 Exploring Factors for Regional Differences in Inappropriate Psychotropic Drug Prescribing: Ecological Study Using a Claims Database in Japan

    Dec 1, 2023, 00:00

  • P30 Do Novel Oncology Combination Therapies Have a Place Within the EU Legislative Framework? The Impact of Challenges for Novel Combination Therapies on Equality of Access Between European Patients

    Dec 1, 2023, 00:00

  • EE674 Healthcare Resource Use and Costs Associated with Endometrial Cancer Treatment in the Private Setting in Brazil

    Dec 1, 2023, 00:00

  • RWD115 Assessing and Comparing Inpatient Hospitalization for Mental Disorders in the United States and European OECD Countries

    Dec 1, 2023, 00:00

  • PCR51 Patient-Centered Instrument Design: Problems and Solutions Based on Patient Feedback

    Dec 1, 2023, 00:00

  • EPH84 Burden of Respiratory Syncytial Virus in Children ≤ 2 Years of Age in Germany: Retrospective Analysis of Health Claims Data from 2014-2019

    Dec 1, 2023, 00:00

  • HTA306 The Combination Conundrum: Comparing Reimbursement Outcomes for Oncology Combination Products in the UK and France

    Dec 1, 2023, 00:00

  • RWD123 The Impact of COVID-19 on Treatment of Patients With Ovarian Cancer in England

    Dec 1, 2023, 00:00

  • HPR95 Public-Private Partnership Model in Oncology: Business Opportunities for Next Generation Contract Research Organizations in the Context of CancerX

    Dec 1, 2023, 00:00

  • PT38 Budget Impact Analysis of rFVIII Glycopegylated-Exei for the Treatment of Haemophilia A in Colombia

    Dec 1, 2023, 00:00

  • PCR113 EQ-5D Studies in Pediaric Diabetes: A Systematic Review

    Dec 1, 2023, 00:00

  • EE173 Budget Impact Analysis of IDegAsp for the Management of Type 2 Diabetes in Saudi Arabia

    Dec 1, 2023, 00:00

  • EE232 Cost-Effectiveness of a Genomic Profiling Test for HRD Determination in Ovarian Cancer Into the Current Clinical Practice for Platinum-Sensitive Patients With Advanced Ovarian Cancer in Greece

    Dec 1, 2023, 00:00

  • CO141 Assessing the Impact of Additional Follow-up Data on Disease-Free Survival (DFS) Projections of Nivolumab and Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC) Patients Within the CheckMate-274 Trial

    Dec 1, 2023, 00:00

  • EE53 An Investigation of Value for Money of Oncology Drugs in Canada

    Dec 1, 2023, 00:00

  • HPR79 Analysis of Newly FDA Approved Medicines and the Licensing Status By Titck in Turkiye

    Dec 1, 2023, 00:00

  • HPR205 Predicting Drug Price Erosion in Germany Associated With Indication Expansion, to Understand the Potential Launch Price Benchmark for a New Product

    Dec 1, 2023, 00:00

  • MSR119 Statistical Methods to Examine Racial and Ethnic Disparities in the Surgical Literature: A Review and Recommendations for Improvement

    Dec 1, 2023, 00:00

  • EE412 Unraveling the Disease Burden of Generalized Pustular Psoriasis: A Comparative Analysis of Flares with Psoriasis Vulgaris in Taiwan

    Dec 1, 2023, 00:00

  • PCR14 Prioritization of Social Disability Management Using a Patient Reported Outcome Questionnaire in Patients Suffering from Multiple Sclerosis (MS)

    Dec 1, 2023, 00:00

  • HPR77 Community-Based Health Insurance and Migrant Organizations: Senegalese Associations’ Response to Legal Vulnerability and Transnational Medical Needs

    Dec 1, 2023, 00:00

  • MT41 Single-Use Vs Reusable Endoscope Reprocessing: A Staff Survey on Safety and Effectiveness

    Dec 1, 2023, 00:00

  • EE307 Drive-the-Doctor Paradigm for Acute Ischemic Stroke with Large Vessel Occlusion: A Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • EE463 Economic Evaluation of Single Pill Combination Clopidogrel: Aspirin Versus Free Combination Clopidogrel Plus Aspirin for Prevention of Cardiovascular Events After Acute Coronary Syndrome in China

    Dec 1, 2023, 00:00

  • MSR117 Identifying Economic Insecurity Among Psoriasis Patients Using Natural Language Processing and Unstructured Clinical Notes

    Dec 1, 2023, 00:00

  • EE700 Are Acute Therapies and Curative Drugs More Affordable Than Chronic Treatments in Rare Diseases? An Analysis of the Top 10 Most Expensive Drugs in the US Compared with Germany

    Dec 1, 2023, 00:00

  • HTA280 Pharmacoeconomic Research As an Area for Drugs Comparison

    Dec 1, 2023, 00:00

  • HTA268 Key Issues in the Methods and Process of Health Technology Assessment in China: A National Expert Survey

    Dec 1, 2023, 00:00

  • HSD11 Hospital Capacity Tool to Assess the Potential Impact of Using a Fixed Dose Combination of Pertuzumab/Trastuzumab for Subcutaneous Injection Versus Intravenous Pertuzumab/Trastuzumab in HER2+ Breast Cancer

    Dec 1, 2023, 00:00

  • HTA44 Broadening the HTA of Medical AI: A Review of Policy Reports to Inform Decision Makers

    Dec 1, 2023, 00:00

  • EE199 A Systematic Literature Review of Economic Evaluations of Community-Based Interventions to Improve Mobility, Continence, and Psychological Wellbeing in Individuals with Neuro-Physical Disabilities

    Dec 1, 2023, 00:00

  • HTA149 Handling Uncertainty in Health-Economic Assessments: Experience From COVID-19 in France

    Dec 1, 2023, 00:00

  • HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG: Status Quo and Quo Vadis

    Dec 1, 2023, 00:00

  • HTA222 Antimicrobial Resistan Evolving Changes in Health Technology Assessment and Reimbursement of New Treatment Options

    Dec 1, 2023, 00:00

  • HPR145 Access of Rare Disease Treatments in the Nordics

    Dec 1, 2023, 00:00

  • EE322 A Cost Analysis for Macrovascular Events, Comparison of Glargine 300U/Ml (GLA-300) and Degludec 100U/Ml (IDeg-100) in the Treatment of Type 2 Diabetes Mellitus in Older Population or Renal Impairment Individuals in Latin America

    Dec 1, 2023, 00:00

  • SA39 Targeted Treatments for Patients with Relapsed and/or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review (SLR) of Randomized Clinical Trials (RCTs)

    Dec 1, 2023, 00:00

  • EE324 Clinical and Economic Evaluation of the Potential Implementation of P4P for Type 2 Diabetes in Bulgaria

    Dec 1, 2023, 00:00

  • HSD79 Assessment of Patient Satisfaction with Public Pharmacies Dispensing High-Cost Drugs in Greece

    Dec 1, 2023, 00:00

  • EE548 Data Availability and Modelling Approaches in Health Economic Evaluation of Cystic Fibrosis: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EPH86 Access to a First Disease-Modifying Therapy Leads to a Disproportionate Increase in the Patient Population Diagnosed with a Rare Disease

    Dec 1, 2023, 00:00

  • PT37 A Systematic Review of Modelling Approaches in Economic Evaluations of Treatments for Inherited Bleeding Disorders

    Dec 1, 2023, 00:00

  • MT39 Development of an Early Economic Model to Assess the Cost-Effectiveness of a Novel Technology for the Treatment and/or Prevention of Cataracts

    Dec 1, 2023, 00:00

  • HTA248 Incorporating Patient Perspectives in HTA Assessments for Rare Diseases: Insights From Multiple HTA Assessments

    Dec 1, 2023, 00:00

  • PCR103 Validating an Herpes Zoster Health Related Quality of Life Conceptual Model in Argentina: Literature Review and Qualitative Study

    Dec 1, 2023, 00:00

  • PCR111 Which Body Functions and Activities Matter for Stroke Patients? Study Protocol for Best–Worst Scalings to Value Core Elements of the ICF

    Dec 1, 2023, 00:00

  • EE504 Buprenorphine–Naloxone Film Yields Cost Savings in Administration Time Compared With Sublingual Tablets in Sweden

    Dec 1, 2023, 00:00

  • PCR63 Health-Related Quality of Life in COVID-19: A Vignette Study

    Dec 1, 2023, 00:00

  • SA45 Natural Evolution of Chronic Kidney Disease in Diabetic Patients: Costs and Consequences in Portuguese Reality

    Dec 1, 2023, 00:00

  • CO56 Radiographic Progression Free Survival as a Surrogate Endpoint for Overall Survival Among Men With Metastatic Castration-Resistant Prostate Cancer

    Dec 1, 2023, 00:00

  • EE389 Collective vs Health Insurance Perspective in a French Efficiency Model: A Diversity of Cost Measurement Sources

    Dec 1, 2023, 00:00

  • HTA316 Understanding the Application of Various Statistical Analysis Methods to Inform Comparative Effectiveness of Ultra Orphan Treatments: A Review of NICE HST Guidance

    Dec 1, 2023, 00:00

  • EE556 Beclometasone/Formoterol/Glycopyrronium Vs. Fixed and Open Combinations of Inhaled Corticosteroids, Long-Acting B2-Agonist, and Long-Acting Muscarinic Antagonist in Adults with Uncontrolled Asthma: A Network Meta-Analysis

    Dec 1, 2023, 00:00

  • MSR30 Existing Practices for the Identification, Selection, or Assessment of Registries and Real-Word Data for Regulatory/HTA Purposes: A More-EUROPA Project Systematic Review

    Dec 1, 2023, 00:00

  • HTA110 Acceptability of Surrogate Endpoints by Health Technology Assessment Bodies: Results from a Systematic Review of Transparency Committee Assessments in France

    Dec 1, 2023, 00:00

  • MSR101 Methodological Insights on Indirect Treatment Comparisons for Ulcerative Colitis Therapies in NICE Submissions

    Dec 1, 2023, 00:00

  • The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non–Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • P14 Understanding Patients' Preferences for Remote Monitoring in Parkinson's Disease: Insights from a Mixed-Methods Study

    Dec 1, 2023, 00:00

  • CO66 Improvements in the Peabody Developmental Motor Scale, Second Edition (PDMS-2) and Correlation With Bayley-III Scores and Motor Milestones in Aromatic L-Amino Acid Decarboxylase Deficiency (AADCd)

    Dec 1, 2023, 00:00

  • EE245 Indirect Cost of Spinal Muscular Atrophy (SMA) in Singapore

    Dec 1, 2023, 00:00

  • EE119 Development of a De Novo Model to Assess the Cost-Effectiveness of a New Treatment Option for Patients With Primary Immunoglobulin a Nephropathy (IgAN)

    Dec 1, 2023, 00:00

  • CO36 Comparative Analysis of Coding Schemas for Assessing Major Bleeding Risk Between Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin

    Dec 1, 2023, 00:00

  • Medical Technologies

    Dec 1, 2023, 00:00

  • HTA240 An Evaluation of the Reimbursement Status of CAR-T Cell Therapies in the EU-4 and UK

    Dec 1, 2023, 00:00

  • OP16 Environmental Sustainability Success Stories From the Pharmaceutical and Medtech Industries in Europe: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • MSR12 Analysis of Long-Term Survivorship (LTS) Rates for Stage 2B/2C Melanoma Using Published Real-World Data (RWD) and Data From Randomized Controlled Trials (RCTS)

    Dec 1, 2023, 00:00

  • EE279 Model-Projected Long-Term Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) Gene-Edited Therapy in Patients with Transfusion-Dependent Beta-Thalassemia in the United Kingdom

    Dec 1, 2023, 00:00

  • OP13 Impact of Pay-for-Performance Programs on Diabetes Management: A Critical Analysis

    Dec 1, 2023, 00:00

  • PT36 Real-World Analysis on Therapeutic Pattern and Economic Burden of Androgen-Receptor Signaling Inhibitors (ARSI) and Taxane-Based Chemotherapy Treated Metastatic Castration-Resistant Prostate Cancer Patients in Italy

    Dec 1, 2023, 00:00

  • PCR48 Health-Related Quality of Life in Children with Pneumococcal Disease: What Can We Learn from Cost-Effectiveness Analyses of Pneumococcal Vaccines?

    Dec 1, 2023, 00:00

  • HPR166 Access to Innovative Treatment Through Performance-Based Contracts in Fran Recommendations From Multidisciplinary Experts’ Workshops

    Dec 1, 2023, 00:00

  • CO96 Myelofibrosis Symptom Assessment Form Total Symptom Score (MFSAF TSS) v4.0: Measurement Properties from the Momentum Phase 3 Study

    Dec 1, 2023, 00:00

  • HTA113 How Have Manufacturers Maximised Their Digital Health Technologies’ Chances of Successful Reimbursement in Germany?

    Dec 1, 2023, 00:00

  • HTA205 EU Joint Clinical Assessments on Health Technologies Is Approaching—Are We Prepared?

    Dec 1, 2023, 00:00

  • HTA143 Drug Market Access Delays in Fran What Role May Cost-Effectiveness Evaluations Play in Varying These Timescales?

    Dec 1, 2023, 00:00

  • EE394 Understanding Reasons of Negative Reimbursement Decisions for Orphan Drugs in the Spanish National Health System (APRIL 2019-MAY 2023)

    Dec 1, 2023, 00:00

  • SA77 Health Technology Assessment (HTA) Feasibility Study: The XprESS Device for the Treatment of Patients With Eustachian Tube Dysfunction

    Dec 1, 2023, 00:00

  • EE443 Burden of Hospitalization Related to Adult Herpes Zoster Infection in Portugal

    Dec 1, 2023, 00:00

  • EE610 Opportunities to Improve the Cost Effectiveness of the Care Pathway in Acute Ischemic Stroke: A Decision Tree Analysis

    Dec 1, 2023, 00:00

  • EE731 Estimating the Economic Impact of Enabling the Digital Transfer of Patients’ Prescription Information in the English National Health Service

    Dec 1, 2023, 00:00

  • EE349 The Impact of Using Real-World Data on the Cost-Effectiveness of Fremanezumab for Migraine Prevention in a UK Healthcare Perspective Analysis

    Dec 1, 2023, 00:00

  • CO166 Efficacy of Lecanemab in Patients With Early Alzheimer Disease: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • PCR136 The Burden of Systemic Mastocytosis in Select European Countries: Evidence from the Prism Patient Survey

    Dec 1, 2023, 00:00

  • RWD124 Characteristics of Patients with Advanced Endometrial Cancer Who Received Pembrolizumab As Part of an Early Access Program (EAP) in Accordance with KN-775 Labelling

    Dec 1, 2023, 00:00

  • EE34 Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Meropenem for the Treatment of Serious Infections Due to Gram-Negative Bacteria for Which There Are Limited Treatment Options (LTO) in Italy

    Dec 1, 2023, 00:00

  • EE570 A Swedish Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease

    Dec 1, 2023, 00:00

  • HPR81 Challenges in the Identification of Unmet Needs in Rare Diseases: Towards the Development of a Framework

    Dec 1, 2023, 00:00

  • EE121 Cost-Efficiency and the Opportunity for Expanded Treatment Access with Incremental Increases in Biosimilar Adalimumab and Tocilizumab Use: A European Perspective

    Dec 1, 2023, 00:00

  • EE544 The Impact of Pulmonary Arterial Hypertension in the Brazilian Public Healthcare System: A Microcosting Approach Based on Expert's Opinion

    Dec 1, 2023, 00:00

  • PT10 Opioid Tapering and Its Associations with Risk of Opioid Use Disorder and Mortality Among Older Adults

    Dec 1, 2023, 00:00

  • EE334 Five-Year Budget Impact of Community-Based HIV Testing Strategies for Oral Pre-Exposure Prophylaxis Scale-up in Western Kenya: A Modeling Analysis

    Dec 1, 2023, 00:00

  • EE602 Examination of Changes Experienced in Prices of Goods and Services That Affect Manufacturing Costs in Health Industry for Slovenia

    Dec 1, 2023, 00:00

  • HTA147 Similarities and Differences Between the HTA Methods for Indirect Comparisons in the EU Joint Clinical Assessment and National Assessments by Member States

    Dec 1, 2023, 00:00

  • EE372 Modeling the Cost-Effectiveness in a Sub-Population: Tepotinib Versus Chemoimmunotherapy (C+IO) in Untreated Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METEX14) Skipping

    Dec 1, 2023, 00:00

  • PCR2 Patients’ and Healthcare Professionals’ Preferences Regarding Lipid-Lowering Therapies for Patients with Very High Cardiovascular Risk and Established Atherosclerotic Cardiovascular Disease

    Dec 1, 2023, 00:00

  • CO187 Relative Effectiveness of Faricimab Vs Aflibercept 8 Mg after Loading Phase in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

    Dec 1, 2023, 00:00

  • EE227 Waldenstrom's Macroglobulinemia: An Overview of Treatment Patterns, Resource Use, and Costs From the Brazilian Private Healthcare Perspective

    Dec 1, 2023, 00:00

  • HTA195 Optimized Recommendations in NICE Technology Appraisals: Permissive or Restrictive?

    Dec 1, 2023, 00:00

  • Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations [Editor's Choice]

    Nov 1, 2023, 00:00

  • Table of Contents

    Nov 1, 2023, 00:00

  • On the (Near) Equivalence of Welfarist and Extra-Welfarist Methods to Value Healthcare With Implications for Assessing Equity [Editor's Choice]

    Nov 1, 2023, 00:00

  • The Feasibility and Validity of Preference-Based Quality of Life Measures With Informal Carers: A Think-Aloud Study

    Nov 1, 2023, 00:00

  • Influence of Self-Reported Health Impairments on German EQ-5D-5L Values

    Nov 1, 2023, 00:00

  • A Comparison of Relative-Efficacy Estimate(S) Derived From Both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons: A Review of Matching-Adjusted Indirect Comparisons

    Nov 1, 2023, 00:00

  • Copyright/Subscription

    Nov 1, 2023, 00:00

  • Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology [Editor's Choice]

    Nov 1, 2023, 00:00

  • Evolving Use of Health Technology Assessment in Medical Device Procurement—Global Systematic Review: An ISPOR Special Interest Group Report

    Nov 1, 2023, 00:00

  • Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions [Editor's Choice]

    Nov 1, 2023, 00:00

  • Can Independently Elicited Adult- and Child-Perspective Health-State Utilities Explain Priority Setting?

    Nov 1, 2023, 00:00

  • UK Valuation of EQ-5D-5L, a Generic Measure of Health-Related Quality of Life: A Study Protocol

    Nov 1, 2023, 00:00

  • Editorial Board

    Oct 30, 2023, 08:36

  • The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE’s New Methods Manual [Editor's Choice]

    Oct 1, 2023, 00:00

  • Assessment of Patient-Reported Outcomes in Industry-Sponsored Phase I Oncology Studies: Considerations for Translating Theory Into Practice

    Oct 1, 2023, 00:00

  • Copyright/Subscription

    Oct 1, 2023, 00:00

  • A Qualitative Investigation to Develop an Adapted Version of the EQ-5D-Y-3L for Use in Children Aged 2-4 Years

    Oct 1, 2023, 00:00

  • A Value Framework to Assess Patient-Facing Digital Health Technologies That Aim to Improve Chronic Disease Management: A Delphi Approach [Editor's Choice]

    Oct 1, 2023, 00:00

  • Recognizing the Broader Value of Meningococcal Vaccination: A Matter of Evidence, Ability, or Willingness?

    Oct 1, 2023, 00:00

  • Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration [Editor's Choice]

    Oct 1, 2023, 00:00

  • Table of Contents

    Oct 1, 2023, 00:00

  • A Decade of Health Innovation: The Impact of New Medicines on Patient Health and the Implications for NICE’s Size of Benefit Multiplier

    Oct 1, 2023, 00:00

  • Adaptive Health Technology Assessment: A Scoping Review of Methods [Editor's Choice]

    Oct 1, 2023, 00:00

  • Extending Beyond Bagust and Beale: Fully Parametric Piecewise Exponential Models for Extrapolation of Survival Outcomes in Health Technology Assessment

    Oct 1, 2023, 00:00

  • Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials

    Oct 1, 2023, 00:00

  • Reporting Answer Categorization and Scoring Methods in the Criteria for Health Economic Quality Evaluation (CHEQUE) Tool

    Oct 1, 2023, 00:00

  • Author Reply

    Oct 1, 2023, 00:00

  • Postacute Expenditures Among Patients Discharged Home After Stroke or Transient Ischemic Attack: The COMprehensive Post-Acute Stroke Services (COMPASS) Trial

    Oct 1, 2023, 00:00

  • Does Scoring Method Impact Estimation of Significant Individual Changes Assessed by Patient-Reported Outcome Measures? Comparing Classical Test Theory Versus Item Response Theory

    Oct 1, 2023, 00:00

  • The Integration of Value Assessment and Social Network Methods for Breast Health Navigation Among African Americans

    Oct 1, 2023, 00:00

  • Comparisons of Medical Cost Trajectories Between Non-Hispanic Black and Non-Hispanic White Patients With Newly Diagnosed Localized Prostate Cancer

    Oct 1, 2023, 00:00

  • Estimating the US Baseline Distribution of Health Inequalities Across Race, Ethnicity, and Geography for Equity-Informative Cost-Effectiveness Analysis [Editor's Choice]

    Oct 1, 2023, 00:00

  • Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review

    Oct 1, 2023, 00:00

  • Editorial Board

    Sep 22, 2023, 12:54

  • Whose Time Trade-Off Should Be Used? Anchoring Discrete Choice Experiment Latent Utilities in Health State Valuation

    Sep 1, 2023, 00:00

  • A New Type 2 Diabetes Microsimulation Model to Estimate Long-Term Health Outcomes, Costs, and Cost-Effectiveness [Editor's Choice]

    Sep 1, 2023, 00:00

  • Impacts of Chronic Obstructive Pulmonary Disease Care Pathway on Healthcare Utilization and Costs: A Matched Multiple Control Cohort Study in Saskatchewan, Canada

    Sep 1, 2023, 00:00

  • “What’s Sex and Gender Got to Do With It?” A Scoping Review of Sex- and Gender-Based Analysis in Pharmacoepidemiologic Studies of Medication Adherence

    Sep 1, 2023, 00:00

  • Reimagining Patient Data Access for Researchers

    Sep 1, 2023, 00:00

  • A Rapid Review on the Value of Biobanks Containing Genetic Information

    Sep 1, 2023, 00:00

  • Streamlining Global and Local Data on HIV: Underscoring Role of Institutions and Ethics in Improving Quality of HIV Research

    Sep 1, 2023, 00:00

  • Data Privacy and Health: How Do We Achieve the Right Balance? [Editor's Choice]

    Sep 1, 2023, 00:00

  • Does EQ-5D Tell the Whole Story? Statistical Methods for Comparing the Thematic Coverage of Clinical and Generic Outcome Measures, With Application to Breast Cancer [Editor's Choice]

    Sep 1, 2023, 00:00

  • Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs [Editor's Choice]

    Sep 1, 2023, 00:00

  • Use of Big Data and Ethical Issues for Populations With Substance Use Disorder

    Sep 1, 2023, 00:00

  • Evaluation of Diversity of Clinical Trials Informing Health Technology Assessments in the United States: A 5-Year Analysis of Institute for Clinical and Economic Review Assessments

    Sep 1, 2023, 00:00

  • A Model for Evaluating Total Costs of Care and Cost Savings of Specialty Condition-Based Care for Hip and Knee Osteoarthritis in an Integrated Practice Unit

    Sep 1, 2023, 00:00

  • Table of Contents

    Sep 1, 2023, 00:00

  • Personal Location as Health-Related Data: Public Knowledge, Public Concern, and Personal Action

    Sep 1, 2023, 00:00

  • Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: A Comprehensive Review of Approaches and Challenges [Editor's Choice]

    Sep 1, 2023, 00:00

  • US Residents’ Preferences for Sharing of Electronic Health Record and Genetic Information: A Discrete Choice Experiment

    Sep 1, 2023, 00:00

  • Mothers’ Views on the Storage and Usage of Their Children’s Biological Material Under the Danish Biobanking Model: A Narrative Approach Using Epistemic Injustice

    Sep 1, 2023, 00:00

  • The Societal Impact of Inclisiran in England: Evidence From a Population Health Approach

    Sep 1, 2023, 00:00

  • Editorial Board

    Sep 1, 2023, 00:00

  • Incorporating Prior Beliefs Into Meta-Analyses of Health-State Utility Values Using the Bayesian Power Prior

    Sep 1, 2023, 00:00

  • Balancing Data Privacy With Access to Health Services and Research: Facilitating Confidential Information Sharing in US Multisystem Collaborations

    Sep 1, 2023, 00:00

  • Copyright/Subscription

    Sep 1, 2023, 00:00

  • The Economic Cost of Thyroid Cancer in France and the Corresponding Share Associated With Treatment of Overdiagnosed Cases [Editor's Choice]

    Aug 1, 2023, 00:00

  • Patients’ and Healthcare Professionals’ Perspectives on Better Use of Patient-Reported Outcome Measures in Head and Neck Cancer

    Aug 1, 2023, 00:00

  • Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality Into Cost-Effectiveness Analysis

    Aug 1, 2023, 00:00

  • A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report [Editor's Choice]

    Aug 1, 2023, 00:00

  • Emulating Target Trials With Real-World Data to Inform Health Technology Assessment: Findings and Lessons From an Application to Emergency Surgery

    Aug 1, 2023, 00:00

  • Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products

    Aug 1, 2023, 00:00

  • Copyright/Subscription

    Aug 1, 2023, 00:00

  • Instructions for Authors

    Aug 1, 2023, 00:00

  • Frameworks for Health Technology Assessment at an Early Stage of Product Development: A Review and Roadmap to Guide Applications

    Aug 1, 2023, 00:00

  • Table of Contents

    Aug 1, 2023, 00:00

  • Comparing Patient-Reported Outcomes Measurement Information System Computer Adaptive Testing With Existing Measures After Operative Interventions for Extremity Fractures

    Aug 1, 2023, 00:00

  • The Healthcare Cost Burden of Asthma in Children: A Longitudinal Population-Based Study

    Aug 1, 2023, 00:00

  • Designing Guidelines for Those Who Do Not Follow Them: The Impact of Adherence Assumptions on Optimal Screening Guidelines

    Aug 1, 2023, 00:00

  • Resurrecting Multiattribute Utility Function: Developing a Value Set for Health Utility for Glaucoma

    Aug 1, 2023, 00:00

  • Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring ME T Exon 14 Skipping

    Aug 1, 2023, 00:00

  • How Uncertainty Matters Under Risk Neutrality

    Aug 1, 2023, 00:00

  • Developing Criteria for Health Economic Quality Evaluation Tool [Editor's Choice]

    Aug 1, 2023, 00:00

  • The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer

    Aug 1, 2023, 00:00

  • Cost-Effectiveness and Long-Term Savings of the Bright Bodies Intervention for Childhood Obesity

    Aug 1, 2023, 00:00

  • Best Practice Recommendations for Electronic Patient-Reported Outcome Dataset Structure and Standardization to Support Drug Development [Editor's Choice]

    Aug 1, 2023, 00:00

  • Editorial Board

    Jul 28, 2023, 10:22

  • Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey

    Jul 1, 2023, 00:00

  • The Associations of Prescription Drug Insurance and Cost-Sharing With Drug Use, Health Services Use, and Health: A Systematic Review of Canadian Studies

    Jul 1, 2023, 00:00

  • Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study

    Jul 1, 2023, 00:00

  • Recommendations on the Selection, Development, and Modification of Performance Outcome Assessments: A Good Practices Report of an ISPOR Task Force

    Jul 1, 2023, 00:00

  • Developing, Selecting, and Modifying Performance Outcome Assessments

    Jul 1, 2023, 00:00

  • Public Preferences for Policies to Promote COVID-19 Vaccination Uptake

    Jul 1, 2023, 00:00

  • Health Technology Assessment–Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England [Editor's Choice]

    Jul 1, 2023, 00:00

  • Valuing the EQ Health and Wellbeing Short Using Time Trade-Off and a Discrete Choice Experiment: A Feasibility Study

    Jul 1, 2023, 00:00

  • Quality-Adjusted Life Expectancy Norms for Italy

    Jul 1, 2023, 00:00

  • Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario? [Editor's Choice]

    Jul 1, 2023, 00:00

  • Deriving Meaningful Aspects of Health Related to Physical Activity in Chronic Disease: Concept Elicitation Using Machine Learning–Assisted Coding of Online Patient Conversations

    Jul 1, 2023, 00:00

  • Table of Contents

    Jul 1, 2023, 00:00

  • Intention to Treat or per Protocol? Overly Optimistic Findings Regarding the Cost-Effectiveness of 99DOTS, a Tuberculosis Digital Adherence Technology

    Jul 1, 2023, 00:00

  • The Value of Vaccines in Maintaining Health System Capacity in England

    Jul 1, 2023, 00:00

  • Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis

    Jul 1, 2023, 00:00

  • Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting

    Jul 1, 2023, 00:00

  • Revising the Suspected-Cancer Guidelines: Impacts on Patients’ Primary Care Contacts and Costs

    Jul 1, 2023, 00:00

  • Targeting Diabetes Prevention to More Disadvantaged Groups Improves Cost-Effectiveness: Implications of Inequality in Type 2 Diabetes From Theoretical Interventions

    Jul 1, 2023, 00:00

  • A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample [Editor's Choice]

    Jul 1, 2023, 00:00

  • Designing a Value-Based Formulary for a Commercial Health Plan: A Simulated Case Study of Diabetes Medications [Editor's Choice]

    Jul 1, 2023, 00:00

  • The Impact of Subclinical Hypothyroidism on the Quality of Life During Pregnancy: Mapping 5-Level Version of EQ-5D and ThyPRO-39

    Jul 1, 2023, 00:00

  • Copyright/Subscription

    Jul 1, 2023, 00:00

  • Methods to Adjust Willingness-to-Pay Measures for Severity of Illness [Editor's Choice]

    Jul 1, 2023, 00:00

  • Use of Utility and Disability Weights in Economic Evaluation of Pediatric Vaccines

    Jul 1, 2023, 00:00

  • Editorial Board

    Jun 28, 2023, 09:01

  • Editorial Board

    Jun 1, 2023, 08:52

  • CO124 Real-World Reduction of Oral Corticosteroid Use in Patients Treated with Dupilumab and with Moderate-to-Severe Asthma

    Jun 1, 2023, 00:00

  • MT38 Novel Data Capture Method for the Identification of Potential Flare Events in Chronic Diseases Via Patient Self-Tracking: Insights from Use Case in Sickle Cell Disease (SCD)

    Jun 1, 2023, 00:00

  • EE45 Cost-Effectiveness of Venetoclax in Combination with Rituximab in Relapsed/Refractory Chroniclymphocytic Leukemia in Four Gulf Countries

    Jun 1, 2023, 00:00

  • EE137 Comparison of the Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed By Alendronate between US Women and Men at Increased Risk of Fracture

    Jun 1, 2023, 00:00

  • Medical Technologies

    Jun 1, 2023, 00:00

  • PCR70 Patient and Physician Concordance in Treatment Satisfaction and Symptom Severity Among Male and Female Myasthenia Gravis Patients in the United States and Five European Countries

    Jun 1, 2023, 00:00

  • CO174 Prescription Patterns of Antidiabetic Agent and Renal Effectiveness Among Patients with Diabetic Kidney Disease

    Jun 1, 2023, 00:00

  • RWD50 Characteristics of Health Insurance Coverage in Patients with Active and Nonactive Progressive Multiple Sclerosis in the United States

    Jun 1, 2023, 00:00

  • EE562 Cost-Effectiveness of the Dengue Vaccine TAK-003 in Thailand

    Jun 1, 2023, 00:00

  • SA33 Healthcare Utilization Among Veterans with Alzheimer's Disease Identified from Clinical Notes

    Jun 1, 2023, 00:00

  • EE248 Patient-Informed Value Elements for Economic Evaluation of Treatment for Major Depressive Disorder: A Systematic Review and Synthesis

    Jun 1, 2023, 00:00

  • Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma

    Jun 1, 2023, 00:00

  • EE258 National Trends in Costs and Site of Service of Infused Disease Modifying Therapies for Multiple Sclerosis

    Jun 1, 2023, 00:00

  • EE424 Economic Burden of Chronic Kidney Disease in India: A Targeted Literature Review

    Jun 1, 2023, 00:00

  • RWD124 Understanding the Value of Chart Abstraction for Assessing Oral Treatment History in the Oncology Outpatient Setting

    Jun 1, 2023, 00:00

  • CO163 Associations between Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIS) and Venous Thromboembolism Among Older Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

    Jun 1, 2023, 00:00

  • EE495 Cost-Effectiveness of Pembrolizumab + Axitinib Versus Nivolumab + Ipilimumab As First-Line Treatment of Advanced Renal Cell Carcinoma in the Private Healthcare System in Brazil

    Jun 1, 2023, 00:00

  • CO36 Keratometry, Intraocular Pressure, and Visual Acuity at the Onset of Ophthalmic Conditions in the Real-World Setting

    Jun 1, 2023, 00:00

  • EPH62 Annual Burden of Non-COVID-19 Respiratory Tract Infections in the Pre- to Post- Pandemic Eras: Analysis from the Anlitiks’ All Payor Claims Database

    Jun 1, 2023, 00:00

  • CO43 Burden of Surgery in Desmoid Tumors

    Jun 1, 2023, 00:00

  • RWD68 Early Optimal Recovery As a Composite Outcome to Measure Value of Care in Patients Undergoing Primary Total Knee Arthroplasty with a New Implant Design

    Jun 1, 2023, 00:00

  • HPR146 Specialty Pharmacy Use and Adherence to Oral Anticancer Medications for Breast Cancer and Prostate Cancer: Implications for Medicare Part D Policy

    Jun 1, 2023, 00:00

  • CO217 Treatment Options for Management of Facial Angiofibroma Associated with Tuberous Sclerosis Complex: A Systematic Review of Evidence of Clinical Effectiveness and Cost-Effectiveness

    Jun 1, 2023, 00:00

  • HTA33 Using the Single Profile Preference Method to Estimate Value Sets for Expanded Descriptive Systems

    Jun 1, 2023, 00:00

  • PCR217 Healthcare Resource Utilization Among Hormone Receptor-Positive and Negative Breast Cancer Patients in the Real-World Setting

    Jun 1, 2023, 00:00

  • EPH26 Barriers to in-Person Focus Group Participation during the Third-Year of COVID-19 Pandemic: A Case Study of Colorectal Cancer (CRC) Screening in Underrepresented Groups

    Jun 1, 2023, 00:00

  • EE37 Economic Burden Associated with Immune-Related Adverse Events Induced By Immune Checkpoint Inhibitors Among Older Adults with Non-Small Cell Lung Cancer

    Jun 1, 2023, 00:00

  • CO103 Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the National COVID Cohort Collaborative (N3C)

    Jun 1, 2023, 00:00

  • RWD105 To What Extent Is Allocation of Higher KDPI Score Kidney Transplantation Occurring in the US?

    Jun 1, 2023, 00:00

  • PCR37 Translation and Cultural Adaptation of the Glaucoma Quality of Life-15 Questionnaire to the Romanian Population

    Jun 1, 2023, 00:00

  • HPR31 Value-Based Purchasing Arrangements in Medicaid Programs: Targeted Review

    Jun 1, 2023, 00:00

  • HPR127 Evaluation of the Spatial Accessibility to Inpatient Services in Beijing, China

    Jun 1, 2023, 00:00

  • EE23 Economic Impact of Discontinuation and Relapse Rates Among Patients with Schizophrenia Newly Initiated on Lybalvi Versus Olanzapine during First Year Use

    Jun 1, 2023, 00:00

  • CO179 Potential Health and Economic Outcomes of a Blood-Based Genomic Test As a Prescreen for Lung Cancer in the US Medicare Population

    Jun 1, 2023, 00:00

  • PCR147 Investigating the Patterns of Health-Related Quality of Life and Factors Associated with It Using Latent Class Analysis Among West Virginians

    Jun 1, 2023, 00:00

  • CO13 Evaluating the Impact of Antibiotic Duration on Superinfection after Controlling for Cumulative Spectrum Scores

    Jun 1, 2023, 00:00

  • HPR51 Should Volume-Based Procurement Price of Comparator be Referenced for Innovative Drugs in National Reimbursement Drug List Negotiation in China?

    Jun 1, 2023, 00:00

  • EE296 The Total Cost of Preeclampsia in the Ecuadorian Health System

    Jun 1, 2023, 00:00

  • EE414 Health Economic Evaluation of Early Initiation of Grass Sublingual Immunotherapy Tablets in Children

    Jun 1, 2023, 00:00

  • HPR131 Examination of CMS National Coverage Analyses and Concordance with Other Decision-Making Bodies

    Jun 1, 2023, 00:00

  • Study Approaches

    Jun 1, 2023, 00:00

  • PCR57 The Role of Patient Activation and Social Support in Health Management Among US Adults with Type 2 Diabetes

    Jun 1, 2023, 00:00

  • HSD5 Patient and Caregiver Spinal Muscular Atrophy (SMA) Treatment Attribute Preferences in Latin America

    Jun 1, 2023, 00:00

  • PCR214 Severe Sialorrhea: Patient Journey and Related Costs Reveal Unmet Medical Needs

    Jun 1, 2023, 00:00

  • HTA49 Cost-Utility Analysis of Pneumococcal Vaccines for Older Adults Available in El Salvador

    Jun 1, 2023, 00:00

  • HTA37 Incorporation of Clinical Experts in Health Technology Assessment: A Literature Review

    Jun 1, 2023, 00:00
  • «
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16 (current)
  • 17
  • 18
  • 19
  • 20
  • »